Hiroshi Miyamoto Lab

Hiroshi Miyamoto

 

Miya's Photo

Hiroshi Miyamoto MD. PhD.         

 

 Assistant Professor of Pathology and Urology

 Surgical pathologist in GU oncology

  Click here for CV.

  Email: Hiroshi_Miyamoto@urmc.rochester.edu

 

 

Dr.Hiroshi Miyamoto's Laboratory

Dr. Hiroshi Miyamoto's Laboratory

 

The Miyamoto Laboratory is investigating the role of steroid hormone receptors in prostate and bladder cancers. Our primary work involves the following:

1. Isolating a new class of androgen receptor antagonists.

2. Investigating novel androgen receptor co-regulators in prostate cancer.

3. Elucidating the underlying mechanisms of how androgens promote bladder carcinogenesis and cancer progression.

 

Laboratory members.
Hiroshi Miyamoto, MD, PhD (PI)
Yichun Zheng, MD
Koji Izumi, MD
Yi Li, MD

 

Dr. Hiroshi Miyamoto Publications (PDF files are available when you click individual publication)

 

1. Gene alterations in genitourinary cancers:

Oncol Res 5:245,1993; Br J Cancer 71:831,1993; Cancer 75:2565,1995; Prostate 27:18,1995; J Urol 154:371,1995; Oncol Res 7: 327,1995; Prostate 27:314,1995; Mol Carcinogen 15:38,1996; J Urol 155:1444,1996; Cancer Genet Cytogenet 88:181,1996; Clin Cancer Res 2:929,1996; Urology 55:679,2000; Prostate 71:1108,2011; Eur Urol 59:1071,2011

 

2. Clinicopathologic analysis of genitourinary cancers:

Nature Clin Prac Oncol 2:236,2005; Am J Surg Pathol 1540,2009; J Urol 182:2274,2009; Hum Pathol 40:1693,2009; Pathol Int 60:1,2010; Am J Surg Pathol 34:418,2010; Am J Surg Pathol 34:502,2010; Am J Surg Pathol 34:569,2010; Arch Pathol Lab Med 134:1160,2010; Urology 76:600,2010; CUAJ 5:E47,2011; Hum Pathol 42:1799,2011; Am J Surg Pathol 35:1706,2011; Hum Pathol 43:115,2012; Urol Int 2012 (in press); Histopathology 2012 (in press); Hum Pathol 2012 (in press)

 

3. Identification of novel anti-androgens with marginal agonist activity:

PNAS 100:4440,2003; J Cell Biochem 91:3,2004; Int J Cancer 116: 866,2005; Bioorg Med Chem 14:5933,2006

 

4. Characterization of androgen receptor co-regulators in prostate cancer:

Lancet 349:852,1997; PNAS 95:5527,1998; PNAS 95:7379,1998; BBRC 248:361,1998; Endocrine 11:195,1999; JBC 277:4609-4617,2002; PNAS 100:5124,2003; JBC 278:19619,2003; Prostate 56:280,2003; Cancer Res 63:4888,2003; Clin Cancer Res 10:2208,2004; Cancer Invest 25:32,2007; Mol Endocrinol 21:343,2007; Endocrinology 148:1340,2007; Cancer Res 68:7110,2008

 

5. Role of adrenal androgens in prostate cancer:

PNAS 95:11083,1998; PNAS 96:11173,1999; Int J Urol 7:32,2000

 

6. Involvement of steroid hormone receptor signals in the initiation and progression of bladder cancer:

JNCI 99:558,2007; BMC Urol 8:7,2008; BJU Int 108:24,2011; Endocr-Rel Cancer 18:451,2011; Curr Cancer Drug Tar 12:14,2012; Mol Carcinogen 2012 (in press); BJU Int 2012 (in press)

  1. Yeh S, Miyamoto H, and Chang C "Hydroxyflutamide may not always be a pure antiandrogen." The Lancet (1997): 349(9055):852-3. PMID: 9121269.

  2. Miyamoto H, Yeh S, Kinoshita H, Fujimoto N, Nishimura K, Inui S, Mizokami A, Uemura H, and Chang C "Androgen receptor and androgen receptor cofactors in prostate." Proc. Jap. Nat. Conf. Andrology, (1997):1-4. PMID: none.

  3. Yeh S, Miyamoto H, Shima H, and Chang C "From estrogen to androgen receptor: a new pathway for sex hormone in prostate." Proc. Natl. Acad. Sci. (1998): 95(10):5527-32.PMID: 9576916.

  4. Miyamoto H, Yeh S, Wilding G, and Chang C "Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells." Proc. Natl. Acad. Sci. (1998) 5(13):7379-84. PMID: 9636157.

  5. Miyamoto H, Yeh S, Huang S-B, Fugimoto N, Hsiao P, Ting H, Inui S, Nishimura K, Wang C, Uemura H, Kang H, and Chang C "The Androgen Receptor Coregulator ARA70." in Molecular Basis of Sex Hormone Receptor Function (Gronemeyer H, Fugymann U and Parczyk ed) (1998) pp. 43-51, Springer, Berlin.

  6. Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, and Chang C "Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells." BBRC. (1998);248(2):361-7.PMID: 9675141.

  7. Miyamoto H, Yeh S, Lardy H, Messing E, and Chang C "Delta5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells." Proc. Natl. Acad. Sci. (1998): 95(19):11083-8.PMID: 9736693.

  8. Yeh S, Chang HC, Miyamoto H, Takatera H, Rahman M, Kang HY, Thin TH, Lin HK and Chang C. Differential induction of androgen receptor transcriptional activity by selective androgen receptor coactivators.Keio J. Medicine (1999):48(2):87-92. PMID: 10405524.

  9. Yeh S, Kang H, Miyamoto H, Nishimura K, Chang H, Fujimoto N, Ting H, Mizokami A, Huang K, and Chang C "Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate DU145 cells." Endocrine (1999): 11(2):195-202. PMID: 10709768.

  10. Chang HC, Miyamoto H, Yeh S, Lardy H, and Chang C "Suppression of Delta5-Androstenediol-induced AR transactivation by selective steroids in human prostate cancer cells." Proc. Natl. Acad. Sci. (1999): 96(20):11173-7.PMID: 10500149.

  11. Miyamoto H, and Chang C "Antiandrogens f"il to block completely the androstenedione-induced mutated androgen receptor transactivation in human prostate cancer cells."International J. Urology (2000): 7(1): 32-4. PMID: 10701889.

  12. Miyamoto H, Rahman M, Takatera H, Kang H, Yeh S, Chang H, Nishimura K, Fujimoto N, and Chang C "A dominant-negative mutant of androgen receptor coregulator, ARA54 inhibits androgen receptor-mediated prostate cancer growth." J. Biol. Chem. (2002):277, 4609-17. PMID: 11673464.

  13. Sampson E, Yeh S. Miyamoto H, Lee DK, Tsi, MY, Wang X, Hsu CL, and Chang C "Interaction of cell cycle regulatory proteins with the androgen receptor." pp 223-238 in Steroid hormones and cell cycle regulation. (Burnstein KL ed). (2002):Kluwer, USA.

  14. Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S and Chang C "Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 mutant in prostate cancer cells." J. Biol. Chem. (2003): 278(22),19619-26. PMID: 12649293.

  15. Rahman MM, Miyamoto H, Lardy H and Chang C ?nactivation of androgen receptor (AR) coregulator ARA55 leads to an inhibition of AR transactivation and a reduction of the agonist activity of antiandrogens in prostate cancer cells." Proc Natl. Acad. Sci. (2003):100(9), 5124-9. PMID: 12700349.

  16. Miyamoto H, Marwah P, Lardy H and Chang C "3_-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity." Proc Natl. Acad. Sci. (2003):100, 4440-4444. PMID: 12672951.

  17. Miyamoto H, Rahman MM and Chang C "Molecular basis for the antiandrogen withdrawal syndrome" J. Cellular Biochemistry. (2004):91(1), 3-12. PMID: 14689576.

  18. Rahman M, Miyamoto H, and Chang C "Androgen Receptor Coregulators in Prostate Cancer Progression: Mechanisms and Clinical Implications." Clinical Cancer Research. (2004):10(7), 2208-19. PMID: 15073094.

  19. Miyamoto H, Messing E and Chang C "Androgen Deprivation Therapy for Prostate Cancer: Current Status and Future Prospects." The Prostate. (2004):61(4), 332-53. PMID: 15389811.

  20. Miyamoto H and Chang C "Hormonal therapy for prostate cancer: clinical and experimental evidence." pp 1-32. in Prostate Cancer: Basic Mechanisms and Therapeutic Approaches. (Chang C ed). (2005): World Scientific. USA.

  21. Miyamoto H, messing E and Chang C "Does androgen deprivation therapy improve treatment outcomes in patients with low- and intermediate-risk prostate cancer" Nature Clinical Pratice: Oncology. (2005):2. 236-7. PMID: 16264955.

  22. Miyamoto H, Altuwaijri S, Cai Y, Messing E and Chang C "Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer." Mol Carcinogen. (2005):44(1):1-10. PMID: 16044418.

  23. Miyamoto H, Marwah P, Marwah A, Yang Z, Chung CY , Altuwaijri1 S, Chang C and Henry Lardy "Identification of steroid derivatives that function as potent antiandrogens" Int. J. Cancer (2005):117(5), 866-72. PMID: 15981214.

  24. Marwah P, Marwah A, Lardy H, Miyamoto H and Chang C "C19-Steroids as androgen receptor modulators: Design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists" Bioorganic & Medical Chemistry. (2006):14(17). 5933-47. PMID: 16759873.

  25. Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, Chen Z, Chen YL, Yao JL, Sant'Agnese A and Chang C "Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth?Mol. Endo. (2006):21(2):343-58. PMID:17082327.

  26. Yang Z, Chang YJ, Miyamoto H, Yeh S, Yao YL, di Sant'Agnese PA, Tsai MY, and Chang C "Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonuleoprotein A1 via interaction with AR coregulator ARA54" Endocrinology. (2006):148(3):1340-9. PMID: 17227886.

  27. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Hu YC, Tsai MY, Yeh S, Messing E and Chang C "Promotion of Bladder Cancer Development and Progression by Androgen Receptor Signals" JNCI, (2007):99: 558 - 68. PMID: 17406000

  28. Yang Z, Chang YJ, Yu IC, Miyamoto H, Wu CC, Yeh S, Merry DE, Sobue G, Chen LM and Chang C "ASC-J9 ameliorates spinal and bulbar muscular atrophyphenotype via degradation of androgen receptor" Nature Medicine, (2007):13(3): 348 - 53. PMID: 17334372.

  29. Miyamoto H, Altuwaijri S and Chang C "Androgen Receptor in Prostate Cancer" Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies (Pestell R and Nevalainen ed) (2008):pp 129-146.

  30. Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC and Chang C "Tissue prostate specific antigen (PSA) facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation" Cancer Research., (2008):68: (17), 7110-19. PMID: 1857426. PMC2587124. NIHMSID # 58471.

Contact us.

For more information on the Miyamoto Laboratory, please contact Dr. Miyamoto at 585-275-1702 or  Hiroshi_Miyamoto@urmc.rochester.edu.

Useful Link

 

Contact

Hiroshi Miyamoto
University of Rochester
Box 626
601 Elmwood Ave.
Rochester, NY 14642

hiroshi-miyamoto@URMC.rochester.edu

Other PIs' Emails

 
Chawnshang Chang, Ph.D.

 

Chawnshang Chang, Ph.D.
Shu-Yuan Yeh, Ph.D.

 

Shu-Yuan Yeh, Ph.D.
Soo OK Lee, Ph.D.

 

Soo OK Lee, Ph.D.
JeffLin's Photo Wen-Jye Lin, Ph.D